Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials

Robert A. Hauser
Nobutaka Hattori
Hubert Fernandez
Stuart H. Isaacson
Hideki Mochizuki

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/neurology_articles
Authors
Robert A. Hauser, Nobutaka Hattori, Hubert Fernandez, Stuart H. Isaacson, Hideki Mochizuki, Olivier Rascol, Fabrizio Stocchi, June Li, Akihisa Mori, Yu Nakajima, Robert Ristuccia, and Peter A. LeWitt
Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials

Robert A. Hausera,∗, Nobutaka Hattorib, Hubert Fernandezc, Stuart H. Isaacsond, Hideki Mochizukie, Olivier Rascolf, Fabrizio Stocchig, June Li, Akihisa Mori, Yu Nakajimah, Robert Ristucciaj and Peter LeWittk

aParkinson’s Disease and Movement Disorders Center, Department of Neurology, University of South Florida, Tampa, FL, USA
bDepartment of Neurology, Juntendo University School of Medicine, Tokyo, Japan
cCenter for Neuro-Restoration, Cleveland Clinic, Cleveland, OH, USA
dParkinson’s Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA
eDepartment of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
fClinical Investigation Center CIC1436, Departments of Neurosciences and Clinical Pharmacology, Parkinson Expert Center, NS-Park/FCRIN Network and NeuroToul COEN Center, CHU de Toulouse, INSERM and University of Toulouse 3, Toulouse, France
gIRCCS San Raffaele Pisana, Rome, Italy
hKyowa Kirin, Inc., Princeton, NJ, USA
iKyowa Kirin Co., Ltd., Tokyo, Japan
jKyowa Kirin, Inc., Bedminster, NJ, USA
kHenry Ford Hospital, West Bloomfield, MI, USA

Accepted 24 August 2021
Pre-press 1 September 2021

Abstract.

Background: Istradefylline is a selective adenosine A2A receptor antagonist for the treatment of patients with Parkinson’s disease (PD) experiencing OFF episodes while on levodopa/decarboxylase inhibitor.

Objective: This pooled analysis of eight randomized, placebo-controlled, double-blind phase 2b/3 studies evaluated the efficacy and safety of istradefylline.

Methods: Istradefylline was evaluated in PD patients receiving levodopa with carbidopa/benserazide and experiencing motor fluctuations. Eight 12- or 16-week trials were conducted (n = 3,245); four of these studies were the basis for istradefylline’s FDA approval. Change in OFF time as assessed in patient-completed 24-h PD diaries at Week 12 was the primary endpoint. All studies were designed with common methodology, thereby permitting pooling of data. Pooled analysis results from once-daily oral istradefylline (20 and 40 mg/day) and placebo were evaluated using a mixed-model repeated-measures approach including study as a factor.
Results: Among 2,719 patients (placebo, \( n = 992 \); 20 mg/day, \( n = 848 \); 40 mg/day, \( n = 879 \)), OFF hours/day were reduced at Week 12 at istradefylline dosages of 20 mg/day (least-squares mean difference [LSMD] from placebo in reduction from baseline [95% CI], –0.38 h [–0.61, –0.15]) and 40 mg/day (–0.45 h [–0.68, –0.22], \( p < 0.0001 \)); ON time without troublesome dyskinesia (ON-WoTD) significantly increased. Similar results were found in the four-study pool (OFF hours/day, 20 mg/day, –0.75 h [–1.10, –0.40]; 40 mg/day, –0.82 h [–1.17, –0.47]). Istradefylline was generally well-tolerated; the average study completion rate among istradefylline-treated patients across all studies was 89.2%. Dyskinesia was the most frequent adverse event (placebo, 9.6%; 20 mg/day, 16.1%; 40 mg/day, 17.7%).

Conclusion: In this pooled analysis, istradefylline significantly improved OFF time and ON-WoTD relative to placebo and was well-tolerated.

Keywords: Adenosine A2A receptor antagonist, istradefylline, Parkinson’s disease, treatment

INTRODUCTION

Levodopa is the cornerstone of treatment for patients with Parkinson’s disease (PD) and generally provides good symptom relief; however, the duration of efficacy (ON time) commonly becomes shorter and increasingly variable over time. In addition, patients experience delays in the onset of benefit. Consequently, many patients start experiencing daily periods during which symptoms return and levodopa does not adequately control symptoms (OFF time) [1]. Current adjunctive, dopaminergic therapies, such as dopamine agonists (DAs) and COMT and MAO-B inhibitors, reduce but do not fully eliminate motor fluctuations. Furthermore, adjunctive dopaminergic therapies may be accompanied by dose-limiting adverse events (AEs), including dyskinesia, drowsiness, nausea, orthostatic hypotension, hallucinations, peripheral edema, and impulse control disorders [2, 3].

Istradefylline is a nondopaminergic medication that is adjunctive treatment to levodopa in combination with an aromatic amino acid decarboxylase inhibitor in adult patients with PD experiencing OFF episodes [4–6]. A selective adenosine A2A receptor antagonist, istradefylline has a xanthine chemical structure and does not interact with dopamine receptors or alter dopamine metabolism; it has low or very weak affinity for other receptors, transporters, and ion channels, such as serotonin and acetylcholine receptors as well as other adenosine receptor subtypes [7].

Most treatments for patients with PD help counter the reduction in striatal dopaminergic stimulation that is central to the disease process. Istradefylline, by contrast, targets adenosine A2A receptors, which are highly localized in parts of the basal ganglia, including the caudate nucleus, putamen, and nucleus accumbens [8–12].

In PD, istradefylline is thought to act via the indirect striatal output pathway of the basal ganglia, which suppresses movement. This pathway, which is excessively activated in PD because of loss of dopamine D2 receptor-mediated inhibitory effect, is known to be regulated by the A2A receptor-mediated excitatory mechanism [10]. Istradefylline blocks adenosine A2A receptors in the striatum and globus pallidus external segment, reducing the excessive output of the indirect pathway that occurs in PD. Consequently, the imbalance between the indirect and direct pathways of the basal ganglia is reduced [6].

Istradefylline has been evaluated in multiple phase 2 and 3 studies [13–19]. In levodopa-treated adults with PD experiencing motor fluctuations, studies have demonstrated that istradefylline was generally well-tolerated, reduced OFF time, and increased ON time without troublesome dyskinesia relative to placebo [13, 15–18]. Previous meta-analyses have suggested that, compared to placebo, istradefylline reduces OFF time and motor symptoms, whereas rates of dyskinesia may increase with treatment [20, 21].

Here, we present individual and pooled analyses of randomized, double-blind, placebo-controlled clinical trials in which istradefylline or placebo was added onto stable therapy with levodopa with or without other anti-Parkinson medications.

MATERIALS AND METHODS

Study design

Eight 12- or 16-week phase 2b/3 randomized clinical trials were conducted in North America, Japan, or internationally (NCT00199394, NCT00199407, NCT00199420, NCT00455507, NCT00456586, NCT00456794, NCT00955526, NCT01968031;
All study sites had local or central Institutional Review Board (IRB) approval, and research was carried out in compliance with the Declaration of Helsinki as currently amended. Six of these studies have been published previously in peer-reviewed literature [13–18]. In total, 3,245 patients were randomized to receive once-daily oral doses of placebo or istradefylline (10, 20, 40, or 60 mg) or multiple daily doses of entacapone (200 mg/dose). Entacapone and istradefylline 10 and 60 mg were evaluated in one study each; istradefylline at 20 mg (6002-US-006, 6002-US-013, 6002-0608, 6002-009, 6002-US-018, and 6002-014) and 40 mg (6002-US-006, 6002-0608, 6002-009, 6002-US-018, 6002-EU-007, 6002-014) per dose [13, 14] were evaluated in six studies each (Supplementary File 1, Supplementary Table 1). Only the placebo and 20 and 40 mg istradefylline treatment groups were selected to be pooled in the present analysis and to be compared with placebo, as the 20 and 40 mg doses are the doses approved for use in clinical practice (Supplementary File 1, Supplementary Figure 1).

Data from all eight randomized controlled trials (RCTs) were pooled for efficacy and safety analyses. A second analysis was performed in which data were pooled from the four studies that were selected by the regulatory authority in the United States for istradefylline’s approval. This analysis is presented to enable readers to better interpret and understand the US product label; these four studies represent the trials that met their primary endpoints by the pre-specified analysis method [4]. All studies were specifically designed to have common methodology (Supplementary File 1, Supplementary Table 2), thus permitting pooling of all 8 studies.

Patients

Eligible patients were ≥30 years old (≥20 years old in 6002-0608 [17] and 6002-009 [18]) and were diagnosed with idiopathic PD based on the United Kingdom Parkinson’s Disease Society (UKPDS) Brain Bank Diagnostic Criteria with a Modified Hoehn and Yahr stage of 2 to 4 in the OFF state (ON state in 6002-014).

Patients received levodopa in combination with carbidopa or benserazide for ≥1 year prior to study entry, were on a stable levodopa regimen for ≥4 weeks prior to randomization, and were experiencing end-of-dose wearing-off with an average of at least 2 (Studies 6002-US-005, 6002-US-006, 6002-0608, 6002-009, and 6002-014) [13, 16–18] or 3 h OFF time/day (Studies 6002-US-013, 6002-US-018, and 6002-EU-007) [14, 15] at baseline (see Supplementary File 1, Supplementary Table 2). Levodopa dosages could be reduced if patients experienced levodopa-related AEs (6002-US-018, 6002-0608, and 6002-009), AEs (6002-US-005, 6002-US-006, and 6002-US-013), or dopamine-related AEs (6002-EU-007) but could not be increased above baseline. Dose changes were not permitted in 6002-014. Patients continued concomitant treatment with other approved anti-Parkinson medications at stable dosages.

Primary endpoints and analysis sets for study endpoints

OFF and ON time recorded in patient-completed 24-h PD diaries provided the primary and secondary change-from-baseline endpoints [22]. The presence of pre-existing dyskinesia was determined using diary records from the week preceding the baseline visit. Change from baseline to Week 12 or End-of-Study in daily OFF time was the primary endpoint of all studies and was reported as either percentage of awake time (% OFF) or hours/day (hours OFF; Supplementary File 1, Supplementary Table 1). In studies where the primary endpoint was recorded as a percentage, data were expressed as hours/day for pooling. Istradefylline had no placebo-adjusted effect on hours asleep/day. Therefore, interconversion of OFF time between percentage of awake time and hours/day permits assessment of statistically significant differences between groups.

ON time was recorded in diaries as occurring with or without dyskinesia. ON time with dyskinesia was reported as non-troublesome (did not interfere with function or cause meaningful discomfort) or troublesome (interfered with function or caused meaningful discomfort) [22]. The sum of ON time without dyskinesia plus ON time with non-troublesome dyskinesia provided the derived variable of ON time without troublesome dyskinesia. Overall, the following parameters were evaluated: total ON time, ON time without dyskinesia, ON time with troublesome dyskinesia, and ON time without troublesome dyskinesia.

Unified Parkinson’s Disease Rating Scale (UPDRS) Part II and III scores in the ON state were recorded in all trials. The Medical Dictionary for Regulatory Activities (MedDRA) version 20.0 was used to classify all AEs reported during the study by System Organ Class and preferred term.
Statistical analysis

Continuous variables were summarized by number of patients, mean, standard deviation (SD), median, minimum, and maximum values. Categorical variables were summarized by number and percentage of patients in each category.

In the pooled analysis, the primary efficacy endpoint was evaluated using a mixed-effect model for repeated measures (MMRM) approach with baseline value as a covariate; fixed-effect terms in the model for study, pooled study center, treatment group, week, and treatment-by-week interaction; and an unstructured covariance matrix. Using this model, the differences in change from baseline to Week 12 for the primary and key secondary efficacy endpoints between each istradefylline treatment group and placebo were estimated based on least-squares (LS) mean difference, with corresponding 95% confidence intervals (CIs) and p values. The LS mean and corresponding 95% CI for the change from baseline to Week 12 for 20 mg, 40 mg and placebo were also estimated from the MMRM. Incidences of treatment-emergent AEs (TEAEs) were summarized by preferred term (MedDRA version 20.0) using the number and percentage of patients reporting an event.

RESULTS

Baseline characteristics and demographics

There were 3245 patients in the eight studies evaluated, including patients who received 10 mg/day istradefylline (n = 149), 60 mg/day istradefylline (n = 155), and entacapone (n = 146). To evaluate approved dosages of istradefylline vs placebo, the pooled population (N = 2719) comprised those patients in the placebo (n = 992), istradefylline 20 mg/day (n = 848), and istradefylline 40 mg/day (n = 879) treatment groups (Supplementary File 1, Supplementary Table 1).

Demographic variables were balanced among treatment groups within each study. Table 1 shows the similarities across studies in intent-to-treat (ITT) populations. Results from the two previously unpublished trials (6002-EU-007 and 6002-014) are shown in Supplementary Files 2 and 3, respectively.

Patient disposition

Of patients randomized in the eight studies, 87.8% to 90.1% completed the 12- or 16-week treatment periods. The most frequent reason for premature discontinuation was AEs (placebo, 1.7% to 7.6%; 20 mg/day, 3.7% to 9.4%, and 40 mg/day, 4.8% to 10.6%), followed by withdrawn consent (placebo, 1.3% to 5.9%; 20 mg/day, 0 to 4.9%; 40 mg/day, 0 to 3.2%; Supplementary File 1, Supplementary Table 3).

Efficacy outcomes: eight-study pool

In the pooled analysis of eight studies, istradefylline reduced mean OFF hours/day at Week 12 relative to placebo at 20 mg/day (LS mean difference from placebo [95% CI], –0.38 h [–0.61, –0.15], p = 0.0011) and 40 mg/day (–0.45 h [–0.68, –0.22], p < 0.0001; Fig. 1A). Total hours/day ON without troublesome dyskinesia significantly increased with istradefylline at 20 mg/day (0.40 h [0.15, 0.66], p = 0.0021) and 40 mg/day (0.33 h [0.08, 0.59], p = 0.0098) compared with placebo (Fig. 1B) The placebo-adjusted effect of istradefylline on the increase in ON time without troublesome dyskinesia was comparable to the decrease in OFF time, and there was no significant difference between istradefylline and placebo in total hours/day of ON time with troublesome dyskinesia in the 20 mg/day (0.08 h [–0.06, 0.21]) and 40 mg/day (0.13 h [0.00, 0.26]) groups (Table 2).

There was a consistent trend toward improvement in UPDRS Part III (ON) scores with istradefylline at both 20 mg/day (–0.6 points [–1.3, 0.1]) and 40 mg/day (–1.3 points [–2.0, –0.6]) relative to placebo (Fig. 1C). Pooled results for all diary endpoints and for UPDRS Parts II and III scores are shown in Table 2.

Safety outcomes

In the pooled safety analysis of all eight studies, the average completion rate was 89.2% across all istradefylline doses and 89.8% for the pooled placebo group. The incidence of TEAEs was generally similar across the three groups (placebo, 65%; 20 mg/day, 71%; 40 mg/day, 70%), and the most frequent AE was dyskinesia (9.6%, 16.1%, and 17.7%, respectively; Table 3), which was mostly mild or moderate in severity and led to discontinuation from study for 0.7%, 0.8%, and 1.5% of patients in the placebo, 20 mg/day and 40 mg/day groups. Dyskinesia was more frequently reported as an AE in istradefylline- and placebo-treated patients with pre-existing dyskinesia noted in baseline diaries (placebo, 14.1%; 20 mg/day, 24.7%; 40 mg/day, 25.9%) compared
# Table 1
## Baseline characteristics and demographics

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (y), n</strong></td>
<td>195</td>
<td>395</td>
<td>225</td>
<td>357</td>
<td>366</td>
<td>584</td>
<td>455</td>
</tr>
<tr>
<td><strong>Mean (SD)</strong></td>
<td>63 (9)</td>
<td>64 (10)</td>
<td>63 (10)</td>
<td>65 (8)</td>
<td>66 (9)</td>
<td>63 (9)</td>
<td>62 (9)</td>
</tr>
<tr>
<td><strong>[range]</strong></td>
<td>[38–87]</td>
<td>[36–87]</td>
<td>[36–87]</td>
<td>[37–84]</td>
<td>[33–84]</td>
<td>[35–85]</td>
<td>[34–87]</td>
</tr>
<tr>
<td><strong>Sex, n (%)</strong></td>
<td>195</td>
<td>395</td>
<td>225</td>
<td>357</td>
<td>366</td>
<td>584</td>
<td>455</td>
</tr>
<tr>
<td><strong>BMI (kg/m²), n</strong></td>
<td>26.7 (5.2)</td>
<td>26.3 (4.5)</td>
<td>27.0 (5.2)</td>
<td>21.9 (3.4)</td>
<td>22.3 (3.5)</td>
<td>28.1 (5.4)</td>
<td>25.3 (4.3)</td>
</tr>
<tr>
<td><strong>[range]</strong></td>
<td>[17.8–57.2]</td>
<td>[15.9–45.4]</td>
<td>[17.2–44.9]</td>
<td>[13.8–32.5]</td>
<td>[19–40.0]</td>
<td>[15.7–54.4]</td>
<td>[14.4–45.2]</td>
</tr>
<tr>
<td><strong>Total OFF time, (hours/day)b, n</strong></td>
<td>195</td>
<td>395</td>
<td>225</td>
<td>357</td>
<td>366</td>
<td>584</td>
<td>455</td>
</tr>
<tr>
<td><strong>Mean (SD)</strong></td>
<td>6.3 (2.6)</td>
<td>5.9 (2.5)</td>
<td>6.6 (2.7)</td>
<td>6.3 (2.6)</td>
<td>6.7 (2.1)</td>
<td>6.4 (2.2)</td>
<td>5.4 (2.0)</td>
</tr>
<tr>
<td><strong>[range]</strong></td>
<td>[0–14.5]</td>
<td>[0.8–14.8]</td>
<td>[2.5–17.8]</td>
<td>[2.0–17.0]</td>
<td>[2.0–16.3]</td>
<td>[2.0–14.0]</td>
<td>[1.0–14.3]</td>
</tr>
<tr>
<td><strong>Total daily dose of levodopa at study entry (mg), n</strong></td>
<td>195</td>
<td>390</td>
<td>224</td>
<td>357</td>
<td>584</td>
<td>454</td>
<td>592</td>
</tr>
<tr>
<td><strong>Median</strong></td>
<td>700</td>
<td>700</td>
<td>700</td>
<td>400</td>
<td>400</td>
<td>750</td>
<td>600</td>
</tr>
<tr>
<td><strong>[range]</strong></td>
<td>[150–4800]</td>
<td>[75–2200]</td>
<td>[150–2100]</td>
<td>[300–1500]</td>
<td>[250–3000]</td>
<td>[105–2000]</td>
<td>[300–3150]</td>
</tr>
<tr>
<td><strong>UPDRS Part III scorec in the ON state, n</strong></td>
<td>195</td>
<td>395</td>
<td>225</td>
<td>357</td>
<td>366</td>
<td>584</td>
<td>455</td>
</tr>
<tr>
<td><strong>Mean (SD)</strong></td>
<td>17.8 (11.1)</td>
<td>17.0 (9.4)</td>
<td>23.4 (11.2)</td>
<td>20.9 (10.3)</td>
<td>21.2 (11.1)</td>
<td>22.1 (11.4)</td>
<td>27.5 (11.8)</td>
</tr>
<tr>
<td><strong>Time since PD diagnosis, y, n</strong></td>
<td>195</td>
<td>395</td>
<td>225</td>
<td>357</td>
<td>366</td>
<td>584</td>
<td>455</td>
</tr>
<tr>
<td><strong>Mean (SD)</strong></td>
<td>9.9 (5.0)</td>
<td>9.5 (5.0)</td>
<td>9.4 (5.1)</td>
<td>8.2 (4.3)</td>
<td>7.7 (4.4)</td>
<td>8.9 (4.8)</td>
<td>8.3 (4.4)</td>
</tr>
<tr>
<td><strong>Time since initiation of levodopa, y, n</strong></td>
<td>195</td>
<td>395</td>
<td>225</td>
<td>357</td>
<td>366</td>
<td>584</td>
<td>455</td>
</tr>
<tr>
<td><strong>Mean (SD)</strong></td>
<td>8.1 (5.1)</td>
<td>8.3 (5.1)</td>
<td>8.6 (5.1)</td>
<td>8.0 (4.3)</td>
<td>7.7 (4.4)</td>
<td>8.9 (4.8)</td>
<td>8.3 (4.4)</td>
</tr>
<tr>
<td><strong>Time since onset of motor complications, n</strong></td>
<td>195</td>
<td>395</td>
<td>225</td>
<td>357</td>
<td>366</td>
<td>584</td>
<td>455</td>
</tr>
<tr>
<td><strong>Mean (SD)</strong></td>
<td>4.1 (3.5)</td>
<td>4.5 (3.9)</td>
<td>3.8 (3.5)</td>
<td>3.3 (2.8)</td>
<td>3.3 (3.1)</td>
<td>3.6 (3.4)</td>
<td>3.1 (2.8)</td>
</tr>
</tbody>
</table>

| Anti-Parkinson medication used at baseline and throughout studyd               | 195 (100.0)           | 395 (100.0)           | 225 (100.0)           | 357 (100.0)       | 366 (100.0)           | 584 (100.0)           | 455 (100.0)       | 592 (100.0)       |
| **Concomitant anti-Parkinson medications, n (%)**                             | 195 (100.0)           | 395 (100.0)           | 225 (100.0)           | 357 (100.0)       | 366 (100.0)           | 584 (100.0)           | 455 (100.0)       | 592 (100.0)       |
| **DOPA and DOPA derivatives**                                                | 195 (100.0)           | 395 (100.0)           | 225 (100.0)           | 357 (100.0)       | 366 (100.0)           | 584 (100.0)           | 455 (100.0)       | 592 (100.0)       |
| **DAs**                                                                       | 150 (76.9)            | 304 (76.2)            | 171 (76.0)            | 330 (92.4)        | 318 (86.9)            | 430 (73.6)            | 226 (49.7)        | 463 (78.2)        |
| **COMT inhibitors**                                                           | 80 (41.0)             | 172 (43.5)            | 101 (44.9)            | 53 (14.8)         | 183 (50.0)            | 278 (47.6)            | 0e                 | 227 (38.3)        |
| **MAO-B inhibitors**                                                         | 33 (16.9)             | 63 (15.9)             | 26 (11.6)             | 186 (52.1)        | 184 (50.3)            | 76 (13.0)             | 38 (8.4)          | 220 (37.2)        |
| **Adamantane derivatives**                                                   | 55 (28.2)             | 110 (27.8)            | 70 (31.1)             | 127 (35.6)        | 134 (36.6)            | 151 (25.9)            | 134 (29.5)        | 194 (32.8)        |
| **Anticholinergics**                                                         | 9 (4.6)               | 18 (4.6)              | 21 (9.3)              | 64 (17.9)         | 50 (13.7)             | 24 (4.1)              | 84 (18.5)         | 27 (4.6)          |
| **Other**                                                                    | 3 (1.5)               | 6 (1.5)               | 0                    | 89 (24.9)         | 122 (33.3)            | 27 (4.6)              | 10 (2.2)          | 10 (1.7)          |

aITT population, total for all treatment groups in the study, including placebo; bObserved case; cUPDRS Part III score = sum of UPDRS questions 18 to 31 (motor examination); dNot collected; eCalculated relative to screening visit date; fPatients shown as receiving DA, COMT inhibitor, or MAO-B inhibitor may have also been receiving other categories of PD medications; gEntacapone was an active comparator in this study; therefore, concomitant COMT inhibitors were not allowed, per protocol; hPrimarily includes domperidone, droxidopa, promethazine, and zonisamide for Studies 6002-0608 and 6002-009; BMI, body mass index; COMT, catechol-O-methyltransferase; DA, dopamine agonist; ITT, intent-to-treat; MAO-B, monoamine oxidase B; PD, Parkinson’s disease; SD, standard deviation; UPDRS, Unified Parkinson Disease Rating Scale.
Fig. 1. Forest plot of 8 randomized trials (MMRM) showing LS mean difference from placebo in the change from baseline to Week 12 in (A) OFF hours/day, (B) hours/day ON without troublesome dyskinesia, and (C) UPDRS Part III ON. The symbol on each horizontal line is the LS mean difference from placebo in the change from baseline for the istradefylline dosage shown at left. The horizontal line is the 95% CI. The 4 studies in orange were included in the US label for istradefylline. For panels A and C, negative values indicate improvement; for panel B, positive values indicate improvement. Open symbols = pooled results; filled symbols = individual study results. CI, confidence interval; MMRM, mixed-model repeated measures; UPDRS Part III, Unified Parkinson’s Disease Rating Scale, Part III (motor function).
Table 2
Efficacy endpoints for the 8- and 4-study pools

<table>
<thead>
<tr>
<th>Efficacy endpoint</th>
<th>LS mean difference from placebo in the change from baseline (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Istradefylline 20 mg/day</td>
</tr>
<tr>
<td>Total OFF time (hours/day)</td>
<td></td>
</tr>
<tr>
<td>8-study pool</td>
<td>–0.38 (–0.61, –0.15)</td>
</tr>
<tr>
<td>4-study pool</td>
<td>–0.75 (–1.10, –0.40)</td>
</tr>
<tr>
<td>ON time without troublesome dyskinesia (hours/day)</td>
<td></td>
</tr>
<tr>
<td>8-study pool</td>
<td>0.40 (0.15, 0.66)</td>
</tr>
<tr>
<td>4-study pool</td>
<td>0.68 (0.31, 1.06)</td>
</tr>
<tr>
<td>Total ON time (hours/day)</td>
<td></td>
</tr>
<tr>
<td>8-study pool</td>
<td>0.48 (0.24, 0.71)</td>
</tr>
<tr>
<td>4-study pool</td>
<td>0.81 (0.46, 1.16)</td>
</tr>
<tr>
<td>ON time without dyskinesia (hours/day)</td>
<td></td>
</tr>
<tr>
<td>8-study pool</td>
<td>0.15 (–0.13, 0.44)</td>
</tr>
<tr>
<td>4-study pool</td>
<td>0.50 (0.10, 0.90)</td>
</tr>
<tr>
<td>ON time with troublesome dyskinesia (hours/day)</td>
<td></td>
</tr>
<tr>
<td>8-study pool</td>
<td>0.08 (–0.06, 0.21)</td>
</tr>
<tr>
<td>4-study pool</td>
<td>0.13 (–0.07, 0.32)</td>
</tr>
<tr>
<td>UPDRS Part II ON (score)</td>
<td></td>
</tr>
<tr>
<td>8-study pool</td>
<td>0.1 (–0.2, 0.4)</td>
</tr>
<tr>
<td>4-study pool</td>
<td>0.19 (–0.19, 0.56)</td>
</tr>
<tr>
<td>UPDRS Part III ON (score)</td>
<td></td>
</tr>
<tr>
<td>8-study pool</td>
<td>–0.6 (–1.3, 0.1)</td>
</tr>
<tr>
<td>4-study pool</td>
<td>–1.36 (–2.34, –0.38)</td>
</tr>
</tbody>
</table>

CI, confidence interval; LS, least-squares; UPDRS, Unified Parkinson’s Disease Rating Scale.

Table 3
Frequency of TEAEs occurring in ≥5% of patients receiving istradefylline 20 or 40 mg/day in the safety population

<table>
<thead>
<tr>
<th>Adverse event, n (%)</th>
<th>Placebo 20 mg/day</th>
<th>Istradefylline 20 mg/day</th>
<th>Istradefylline 40 mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>8-study pool, n</td>
<td>1010</td>
<td>869</td>
<td>896</td>
</tr>
<tr>
<td>Any TEAE</td>
<td>661 (65.4)</td>
<td>614 (70.7)</td>
<td>628 (70.1)</td>
</tr>
<tr>
<td>Dyskinesia</td>
<td>97 (9.6)</td>
<td>140 (16.1)</td>
<td>159 (17.7)</td>
</tr>
<tr>
<td>Nausea</td>
<td>46 (4.6)</td>
<td>52 (6.0)</td>
<td>54 (6.0)</td>
</tr>
<tr>
<td>Fall</td>
<td>50 (5.0)</td>
<td>35 (4.0)</td>
<td>45 (5.0)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>42 (4.2)</td>
<td>44 (5.1)</td>
<td>44 (4.9)</td>
</tr>
<tr>
<td>Constipation</td>
<td>33 (3.3)</td>
<td>50 (5.8)</td>
<td>48 (5.4)</td>
</tr>
<tr>
<td>Insomnia</td>
<td>42 (4.2)</td>
<td>31 (3.6)</td>
<td>48 (5.4)</td>
</tr>
<tr>
<td>4-study pool, n</td>
<td>426</td>
<td>356</td>
<td>378</td>
</tr>
<tr>
<td>Any TEAE</td>
<td>278 (65.3)</td>
<td>241 (67.7)</td>
<td>263 (69.6)</td>
</tr>
<tr>
<td>Dyskinesia</td>
<td>32 (7.5)</td>
<td>52 (14.6)</td>
<td>63 (16.7)</td>
</tr>
<tr>
<td>Nausea</td>
<td>20 (4.7)</td>
<td>15 (4.2)</td>
<td>24 (6.3)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>16 (3.8)</td>
<td>11 (3.1)</td>
<td>21 (5.6)</td>
</tr>
<tr>
<td>Constipation</td>
<td>12 (2.8)</td>
<td>19 (5.3)</td>
<td>21 (5.6)</td>
</tr>
<tr>
<td>Insomnia</td>
<td>15 (3.5)</td>
<td>2 (0.6)</td>
<td>21 (5.6)</td>
</tr>
<tr>
<td>Viral upper respiratory tract infection</td>
<td>20 (4.7)</td>
<td>22 (6.2)</td>
<td>20 (5.3)</td>
</tr>
</tbody>
</table>

TEAE, treatment-emergent adverse event.

with patients without pre-existing dyskinesia (placebo, 3.5%; 20 mg/day, 4.4%; 40 mg/day, 8.4%).

In istradefylline-treated patients, there was little or no increase in the incidence of AEs commonly observed in patients with PD during treatment with levodopa and other dopaminergic anti-Parkinson medications (nausea and vomiting, hallucinations, impulse control disorders, orthostatic hypotension, somnolence/sleepiness) (Supplementary File 1, Supplementary Table 4). No clinically meaningful changes in laboratory parameters, vital signs, or ECG parameters were observed.

**Efficacy and safety outcomes: four-study pool**

In the pooled analysis of four studies, the LS mean difference from placebo in the change from baseline in total OFF hours/day at Week 12 was –0.75 h (95%
addition to a background of levodopa/decarboxylase medication. Therefore, all results were obtained in and 95% were receiving additional anti-Parkinson fylline. All randomized patients received levodopa, analyses demonstrated consistent effects of istrade-istradefylline’s US product label. Importantly, these better interpret and understand the data that underlies selected by the US FDA in order to enable readers to vide a pooled analysis of the four studies that were two previously unpublished studies, and 2) we pro-
in phase 2b/3 double-blind clinical trials, including as adjunctive treatment for patients with OFF time,

in the present analysis, if dyskinesia became problematic, the levodopa dose could be reduced. However,
in a proof-of-concept study, istradefylline added to a low-dose IV levodopa infusion potentiated the antiparkinsonian response and caused less dyskinesia compared with that induced by an optimal-dose IV levodopa infusion alone [25]. This strategy of lowering the levodopa dose and adding istradefylline has
not yet been tested in patients with PD and dyskinesia on oral levodopa but remains of interest for future trials.

For new drug applications, the U.S. Food and Drug Administration requires “substantial evidence” of drug safety and efficacy and interprets this as needing at least two adequate and well-controlled phase 3 trials with convincing evidence of effectiveness [26]. For the US approval of istradefylline, four clinical trials were included in the label to support its safety and efficacy. In these trials, istradefylline doses of 20 mg/day (6002-US-013, –0.62 h; 6002-0608, –0.67 h; 6002-009, –0.67 h) and 40 mg/day (6002-US-005, –1.11 h; 6002-0608, –0.84; 6002-0609, –0.71 h) significantly reduced OFF time compared with placebo. The magnitude of the OFF time reduction in the 4-study pool was somewhat greater than the reduction observed in the more comprehensive 8-study pool, which would be expected given that these 4 trials were selected based on their positive results in the primary analysis. ON time without troublesome dyskinesia and UPDRS scores also showed a somewhat larger magnitude of change in the 4-study pool.

Experience with adenosine A2A antagonists suggests variability in outcome across trials, probably owing to issues of study conduct. In a phase 2 trial of preladenant, 5 mg BID reduced OFF time compared with placebo by 1.0 h ($p = 0.0486$) and 10 mg BID by 1.2 h ($p = 0.019$) [27]. However, in two phase 3 trials, preladenant failed to significantly reduce OFF time compared with placebo. Notably, rasagiline was included as an active control in one of the phase 3 studies, and it also failed to significantly reduce OFF time compared with placebo [28]. Although methodologic issues that could have accounted for these results were identified, further development of preladenant was discontinued.

In clinical trials of the adenosine A2A receptor antagonist tozadenant, reduction in daily OFF time relative to placebo was variable, ranging from –1.2 h in the initial phase 2b study to –0.83 in the phase 3 trial, the latter of which is comparable to the present findings [29, 30]. However, clinical development of tozadenant was prematurely terminated due to agranulocytosis and 7 cases of sepsis, with 5 of 7 ending in death [31]. The present analysis found that rates of neutropenia, including agranulocytosis, in istradefylline-treated patients were low in both the 8- (20 mg/day, 0.5%; 40 mg/day, 0.8%) and 4-study (20 mg/day, 0.3%; 40 mg/day, 0.5%) pools (Supplementary File 1, Supplementary Table 4).

The magnitude of reduction in OFF time with istradefylline (20 or 40 mg/day) in the current pooled analysis is generally in the range reported in a Cochrane review of efficacy and safety of adjunctive treatments to levodopa therapy in PD patients with motor complications [2]. Safinamide 50 mg and 100 mg reduced daily OFF time in two studies, with an LS mean difference from placebo of –0.5 to –1.0 h [32]. Opicapone 50 mg reduced daily OFF time by –0.9 h (LS mean difference from placebo) in 2 registration studies [33]. In the 4-study pool reported here, istradefylline 20 mg/day and 40 mg/day reduced daily OFF time, with an LS mean difference from placebo ranging from –0.6 to –1.1 h.

The purpose of our analyses was to provide a transparent overview of the eight phase 2b/3, placebo-controlled studies of istradefylline as an adjunct to levodopa, including two that were previously unpublished, as well as the subset of four trials that were used by the FDA as the basis for istradefylline’s approval. A strength of our analysis is the large patient population evaluated and the inclusion of multiple, similarly designed studies, which facilitated pooling. Another strength of this analysis is that patients could be on multiple anti-PD medications, which enabled the study population to reflect treatment patterns likely observed in real-world clinical practice. A potential weakness of our analysis is that minor differences in study design, such as location, number of diary entries, and the guidance around adjusting dopaminergic therapies during treatment, led to some heterogeneity between trials that could have affected results of individual studies and complicated interpretation of this pooled analysis. Additionally, pooling of data can inherently lead to over-powering, where positive outcomes (efficacy endpoints) may appear stronger than in the original, individual studies.

This post hoc, pooled analysis demonstrated that istradefylline (20 and 40 mg/day) significantly improved OFF time and ON time without troublesome dyskinesia in patients with PD treated with levodopa and other concomitant anti-Parkinson medications. Motor function (UPDRS Part III ON) also showed a trend toward improvement. These improvements in PD symptoms occurred when istradefylline was administered in addition to a variety of other anti-Parkinson medications, yet there was little to no increase in AEs typically associated with dopaminergic therapies. As many patients with PD continue experiencing motor fluctuations despite available dopaminergic therapies, additional options are needed to provide symptom relief. The...
findings of this analysis indicate that targeting the adenosine A2A receptor in the indirect pathway of the basal ganglia facilitates an improvement in OFF time and PD symptoms in patients on dopamine-targeting therapies. This inclusive analysis of eight randomized, placebo-controlled trials affords clinicians an overview of istradefylline’s efficacy, safety, and tolerability. Istradefylline was generally well-tolerated and provided a clinical benefit in patients with PD who continued to experience motor fluctuations.

ACKNOWLEDGMENTS

The authors and investigators would like to thank the patients and caregivers who participated in these studies. They would also like to thank Phyllis Salzman, PhD (Kyowa Kirin Pharmaceutical Development) and Keizo Toyama (Kyowa Kirin Co., Ltd.,) for their contributions to the summarization of results. Meghan Sullivan, PhD, and Anthony DiLauro, PhD, of MedVal Scientific Information Services, LLC, provided medical writing and editorial assistance, which were funded by Kyowa Kirin, Inc. This manuscript was prepared according to the International Society for Medical Publication Professionals’ “Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3.” Development of this manuscript was funded by Kyowa Kirin, Inc. Kyowa Kirin Pharmaceutical Development, Inc., consulted with advisors and study investigators on the design of these studies, provided financial and material support for these studies, and, with the assistance of study investigators, monitored the conduct of these studies, collected data from the investigative centers, and analyzed the data.

CONFLICT OF INTEREST


**HF:** Research Funding/Investigator: Acorda, Alkahest, Amneal, Biogen, Michael J. Fox Foundation, Movement Disorders Society, NIH/NINDS, Parkinson Study Group, and Sunovion; Honoraria: Bial Neurology, Biopas, Boston University, Cerevel, Cleveland Clinic, CNS Ratings, Covance, Kyowa Hakko Kirin, New York University, Parkinson Study Group, Partners Healthcare System, Revance, Sun Pharma, and Sunovion Research and Development Trust; Royalties From Book Authorship/Editorial Work: Demos Publishing and Springer Publishing. Dr. Fernandez receives compensation from Elsevier as Editor-in-Chief of Parkinsonism and Related Disorders. Dr. Fernandez is contacted by Teva as a co-principal investigator in global studies of deuteretabenazine for tardive dyskinesia.


**OR:** Research Funding/Investigator: Agence Nationale de la Recherche (ANR), CHU de Toulouse, European Commission (FP7, H2020), France-Parkinson, INSERM-DHOS Recherche Clinique Translational, Michael J. Fox Foundation, Programme Hospitalier de Recherche Clinique; Advisory/Consultant: AbbVie, Acorda, Addex, Alzprotekt, ApoPharma, AstraZeneca, Bial, Biogen, Britannia, Bukwang, Cerevel, Clevelex, IRLAB, Lilly, Lundbeck, Lupin, Merck, Mundipharma, NeurATRIS, Neuroderm, Novartis, ONO Pharma, Orion, Osmotica, Oxford Biomedica, Parexel, Pfizer, Prexton, Quintiles, Sanofi, Servier, Sunovion, Theranexus, Takeda, Teva, UCB, Watermark Research, XenoPort, XO, Zambon.

**FS:** Advisory Boards: BIAL, Biogen, Britannia, Chiesi Farmaceutici, Cynapsus, Impax Laboratories, Kyowa Kirin Pharmaceutical Development, Lundbeck A/S, NeuroDerm, Sunovion, UCB, and Zambon.

**JL, AM, YN, RR:** Employment, Kyowa Kirin.

**PL:** Advisor/Consultant: Abide, Acadia, Acorda, Biogen, Britannia, Bukwang, Cynapsus, Impax, Insightec, Intec Pharma, Kyowa Hakko Kirin,
PRIOR PRESENTATIONS

Results reported here were presented as posters at the Parkinson Study Group Annual meeting (April 5–8th, 2019, Chandler, AZ), the 13th World Congress on Controversies in Neurology (April 4–7th, 2019, Madrid, Spain), the World Parkinson’s Congress (June 4–7, 2019, Kyoto, Japan), and the International Congress on Controversies in Neurology Annual Meeting (May 4–10th, 2019, Philadelphia, PA), the World Parkinson’s Congress (June 4–7, 2019, Madrid, Spain), the American Academy of Neurology Annual Meeting (May 4–10th, 2019, Philadelphia, PA), the World Parkinson’s Congress (June 4–7, 2019, Kyoto, Japan), and the International Association of Parkinsonism and Related Disorders Annual Meeting (June 16–19, 2019, Montreal, Canada).

SUPPLEMENTARY MATERIAL

The supplementary material is available in the electronic version of this article: http://dx.doi.org/10.3233/JPD-212672.

REFERENCES


